Centinel Spine® Continues Launch of New Portfolio of prodisc® Cervical Total Disc Replacement Devices & Features at NASS 2022
Centinel Spine now has four FDA-approved cervical total disc replacement devices for 1-level indications, offering the broadest spectrum of solutions to address surgeon preference and individual patient anatomy.
- Centinel Spine now has four FDA-approved cervical total disc replacement devices for 1-level indications, offering the broadest spectrum of solutions to address surgeon preference and individual patient anatomy.
- WEST CHESTER, Pa., Oct. 4, 2022 /PRNewswire/ -- Centinel Spine, LLC, a leading global medical device company addressing cervical and lumbar spinal disease through anterior surgical access, today announced continued expansion of the availability of the prodisc Cervical Total Disc Replacement (TDR) portfolio that allows the disc to be matched to patient anatomy.
- In July, the company received U.S. Food and Drug Administration approval for 1-level indications for prodisc C Vivo, prodisc C SK, and prodisc C Nova.
- The new prodisc portfolio of cervical and lumbar TDR products will be featured at the Centinel Spine booth #4224, as well as multiple podium presentations during NASS 2022.